Combination of Selective Inhibitor of Nuclear Export (SINE) Compounds, Selinexor and KPT-8602, with Venetoclax (ABT-199) Displays Enhanced Activity in Leukemia and Large Cell Lymphoma

MLA

Fischer, Melissa A., et al. “Combination of Selective Inhibitor of Nuclear Export (SINE) Compounds, Selinexor and KPT-8602, with Venetoclax (ABT-199) Displays Enhanced Activity in Leukemia and Large Cell Lymphoma.” Blood, vol. 128, no. 22, Dec. 2016, p. 3949. EBSCOhost, https://doi.org/10.1182/blood.V128.22.3949.3949.

APA

Fischer, M. A., Friedlander, S., Hogdal, L., Arrate, P., Chang, H., Kashyap, T., Argueta, C., Klebanov, B., Senapedis, W., Baloglu, E., Lee, M. S., Shacham, S., & Savona, M. R. (2016). Combination of Selective Inhibitor of Nuclear Export (SINE) Compounds, Selinexor and KPT-8602, with Venetoclax (ABT-199) Displays Enhanced Activity in Leukemia and Large Cell Lymphoma. Blood, 128(22), 3949. https://doi.org/10.1182/blood.V128.22.3949.3949

Chicago

Fischer, Melissa A., Sharon Friedlander, Leah Hogdal, Pia Arrate, Hua Chang, Trinayan Kashyap, Christian Argueta, et al. 2016. “Combination of Selective Inhibitor of Nuclear Export (SINE) Compounds, Selinexor and KPT-8602, with Venetoclax (ABT-199) Displays Enhanced Activity in Leukemia and Large Cell Lymphoma.” Blood 128 (22): 3949. doi:10.1182/blood.V128.22.3949.3949.